Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients

• Status: Recruiting
• Trial end date: 2021-04-10
• Target enrollment: 0
• Participant gender: All

Summary

efficacy and safety of Sofosbuvir containing regimens in treatment of COVID-19 Egyptian patients,

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Ledipasvir; Ribavirin; Sofosbuvir

Criteria

Inclusion Criteria:

• COVID 19 positive patients

Exclusion Criteria:

• COVID-19 patients with critical manifestations.

• Sepsis.

• Acute respiratory distress syndrome (ARDS).

• Decompensated liver disease (Child-Pugh class B or C disease).

• Chronic renal impairment.

• Patients with blood diseases (severe anemia, thalassemia, ITP, leukemia ….).

• Ischemic heart disease within the last 6 months.

• Chronic pulmonary disease.

• Malignancy.

• Pregnancy or breastfeeding.

• Hypersensitivity to sofosbuvir or ribavirin.

• Patients with organ transplant.

• Unwilling to participate in our study